4//SEC Filing
Ward Shane 4
Accession 0001610618-25-000100
CIK 0001610618other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 7:40 PM ET
Size
13.8 KB
Accession
0001610618-25-000100
Insider Transaction Report
Form 4
Ward Shane
COO & CLO
Transactions
- Sale
Common Stock
2025-12-10$220.08/sh−9,959$2,191,747→ 25,033 total - Tax Payment
Common Stock
2025-12-10$219.60/sh−15,041$3,303,004→ 24,633 total - Exercise/Conversion
Common Stock
2025-12-10$16.65/sh+3,500$58,289→ 28,133 total - Exercise/Conversion
Common Stock
2025-12-10$20.20/sh+6,459$130,472→ 34,592 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-10−3,500→ 0 totalExercise: $16.65Exp: 2032-03-30→ Common Stock (3,500 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-10−6,459→ 6,207 totalExercise: $20.20Exp: 2033-03-26→ Common Stock (6,459 underlying)
Footnotes (5)
- [F1]Shares withheld for taxes on RSU vesting.
- [F2]Includes 400 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP), representing 200 shares purchased on each of the following dates: May 20, 2025; and November 20, 2025.
- [F3]The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022.
- [F4]The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
- [F5]The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023.
Documents
Issuer
Cidara Therapeutics, Inc.
CIK 0001610618
Entity typeother
Related Parties
1- filerCIK 0001638380
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 7:40 PM ET
- Size
- 13.8 KB